Discuss your experiences with the benefits, risks, and side effects of immunotherapy treatment for breast cancer.
Posted on: Dec 18, 2018 02:21PM
New Analysis Shows Immunotherapy Tecentriq Only Effective in PD-L1-Positive Breast Cancer
December 14, 2018
A new analysis of the IMpassion130 trial found that the immunotherapy Tecentriq (chemical name: atezolizumab) in combination with the chemotherapy Abraxane (chemical name: albumin-bound paclitaxel or nab-paclitaxel) only helps treat cancers that are PD-L1-positive. Read more...